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Predictive, Preventive and Personalized Medicine (PPPM)
not only offers reduced patient suffering, but also a
reduction in the proportion of GNP needed for health-
care. Yet there is little public pressure for PPPM. Presses
announcements continue to convince patients that the
cures they have been promised are just around the cor-
ner, and the industry is happy to see things continue this
way. Clearly, legislators need to take the lead if there is
ever to be any serious exploration of PPPM in Medicine.
For example, a decade ago, I and my colleagues devel-
oped a detailed understanding of how the Human Micro-
biome causes chronic disease, especially those diagnoses
thought to be ‘autoimmune’. We also retargeted an
approved, widely available pharmaceutical to prevent that
autoimmune disease from getting worse, and in many
case to actually reverse it. Our collaborating physicians
have demonstrated success with hundreds of patients -
yet some of them have been savagely attacked by their
peers. For example, a complaint was laid with the College
of Physicians and Surgeons of British Columbia against
one of my Canadian colleagues, a coauthor of our peer-
reviewed papers, alleging that he wasn’t adhering to
“standard of care” during his successful science-based
treatment of a patient with refractory, idiopathic, disease.
In this case ‘the system’ worked, and his College deter-
mined that the physician had properly used a “rationale
for the knowledge base and guidelines, accessible in peer-
reviewed medical literature, including two papers, from
the prestigious “Annals of the New York Academy of
Sciences.” However, an essentially identical complaint
was laid against a physician in Washington State, who
was only able to retain her license by promising never to
use this new science again, and to have her prescribing
activities supervised by a Preceptor. Worse, in Arizona, a
practitioner was arrested and charged with “Criminal
Child and Vulnerable Adult Abuse.” She has lost her
license, and is waiting to hear if she will go to jail. This
on substantially the same accusation and evidentiary base
as was dismissed in Canada. How are our Universities to
focus on ingenious and imaginative scientific solutions
when Police are tasked to enforce ‘the standard of care’?
Legislators have a responsibility to determine public prio-
rities, and make sure that Industry – all industries, even
the Healthcare Industry – are attentive to them. In 2006,
California passed simple (and successful) legislation to
ensure that a physician or surgeon will not be subject to
discipline for suggesting innovative therapies if he/she
makes sure the patient is aware of ‘the standard of care’
and gives informed consent. The preamble notes that “it
can take up to 17 years for a new best practice to reach
the average physician and surgeon, it is prudent to give
attention to new developments.” Europe is not immune
from the pressures working against innovation, encourage-
ment of pharmacists to second-guess the judgement of
physicians has been particularly damaging to the adoption
of new therapeutic modalities. Yet the California experi-
ence makes it clear that change in Medicine can be pro-
moted with enlightened legislation. Changing the current
healthcare focus to one of PPPM will require leadership,
and the EU is in the box seat to provide that leadership.
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